ReviewHuman genetics2025
Is cross-border transfer of China's human genetic data an impossible mission?
Review in Human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration.Frontiers in immunology · 2026Pooled it
- Management discussion of laws and regulations on human genetic resources in China: a scoping review.BMC medical ethics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cross-border transfer of human genetic data is a crucial prerequisite for sharing such data globally. However, given the unique nature of human genetic data, this aspiration may not be easily realized. China, a country rich in biological resources, possesses a vast wealth of human genetic data. However, due to China's domestic laws and policies, human genetic data is considered both personal information, subject to regulations like the Personal Information Protection Law, and human genetic resources, governed by the Regulations on Management of Human Genetic Resources. This dual nature necessitates a double security review of human genetic data for cross-border transfer, rendering cross-border transfer of China's human genetic data a seemingly impossible mission. However, in recent years, China has refined its security review rules for cross-border data transfer to increase transparency and, in practice, has eased review criteria, issuing numerous administrative licenses. Such a shift of stance is not fortuitous but rather a planned and purposeful reflection of China's top-level design to promote self-reliance and self-improvement in science and technology, as well as its strategic goal of joining international digital economy organizations.
Indexed as
Identifiers
40488785What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.